SCHEMBL21995466

SCHEMBL21995466

C[C@H](O)[C@@H](Nc1c([N+](=O)[O-])cnc2ccccc12)C(C)(C)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPK1 P28482 2/20 0.38
RAB9A P51151 2/20 0.38
LRRK2 Q5S007 1/20 0.38
POLB P06746 2/20 0.36
ALDH1A1 P00352 3/20 0.35
ABCG2 Q9UNQ0 2/20 0.35
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21995467 1.00 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL28684165 0.87 MAPT (0.40) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL28684164 0.87 MAPT (0.40) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL10448992 0.84 MAPT (0.42) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL21995573 0.84 SMN1; SMN2 (0.34) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL21995574 0.84 SMN1; SMN2 (0.34) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL29508379 0.83 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL22749265 0.83 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL22749266 0.83 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL29508391 0.82 MEN1 (0.42) MAPTMEN1KMT2ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed
EP-3887369-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M Innovative Properties Company (US) 2021-10-06 EP disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 CN disclosed
WO-2020109898-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG MAPT 2090/4885MEN1 2108/4885KMT2A 3885/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 MAPT 4748/4885MEN1 1417/4885KMT2A 3602/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 MAPT 4602/4885MEN1 1700/4885KMT2A 3043/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 MAPT 4602/4885MEN1 1700/4885KMT2A 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.